BioLargo, Inc. · OTC:BLGO
BioLargo — Q3 2025 Earnings Presentation
32 slides from BioLargo's earnings presentation, Nov 14, 2025
Slide 1: We Make Life Better
We Make Life Better ) BioLargo The innovation engine for a better tomorrow Q3 2025 Earnings Call Stock Symbol: Presentation OTCQX:BLGO
Slide 2: Safe Harbor Statement
Safe Harbor Statement
Slide 3: Who we are
Who we are > Innovators, > Passionate about > Driven by a mission scientists, engineers, sustainability and to make life better and entrepreneurs human health
Slide 4: What we do
What we do > Best-in-class > Focus on problems > Aim for solutions for without good partnerships and cleantech problems solutions spin-outs to capitalize on our IP Biobargo
Slide 5: The BioLargo Innovation Engine
The BioLargo Innovation Engine (CEES BioLargo We Make Life Better \GpBioLargo = beeety Investing in... 1 BioLargo EN=RGY TECHNOLOGIES @ civra a ee =. BioLargo GBitewe | 5
Slide 6: The Unseen Value of the BioLargo Portfolio
TECHNOLOGIES: The Unseen Value of the BioLargo Portfolio ENERGY + Unmatched technologies + Capital-conserving strategy + Highly qualified people + Driven for high impact oye CNIS snneNTaAL ~ oe These are targeted minimum future values for our portfolio companies, based on management's modeling. This
Slide 7: BioLargo Value: The sum of the parts bull case debate
BioLargo Value: “The sum of the parts bull case debate” ‘Approx % BLGO as Gener? last report Royalty Potential* Benchn Battery $44 Million $2.5 Billions 95% iv) Medical $95 Million —$1Billion+ 49% PFAS $60 Million* $750 Million+ 100% Odor $40 Million* $100 Million+ 100% Engineering NA NA 70/30% prof
Slide 8: Clyra Medical: Entering the Next Stage of Commercialization
+ FDA Cleared * Major distribution agreements already signed and preparing to launch sales + New distributor Advanced Solution* CLYR nN + Expanded Market Access — Hederltesinelsszele * U.S. & international markets * 6,100 hospitals, 6,300 surgery centers, and Entering the Next Stage 2,200 wound care
Slide 9: Clyra Medical Technologies Update
Clyra Medical Technologies CLYRA’ Medical Technologies Ine Update * Achieved noteworthy progress across product development, commercialization, and clinical programs, advancing toward multiple near-term market launches and international expansion; initial commercialization targeting $732 million wou
Slide 10: Energy Technologies: Liquid Sodium Battery
ENERGY \OO} TECHNOLOGIES C=LLI N ITY Liquid Sodium Battery pita | 0
Slide 11: Clean energy's next trillion-dollar business
onl Ouprtona Clean energy’s next trillion-dollar business Grits baere retaking off tt ia/i “global energy storage experts have predicted the global supply of battery energy storage will need to increase from today's 200 gigawatts to more than a terawatt by 2030 and more than five terawatts by 2050,
Slide 12: The Problems with Lithium Batteries
The Problems with Lithium Batteries > Explosive > High risk of thermal runaway > Global supply chain risk > Poor environmental outcomes
Slide 13: Celinity battery technology vs lithium-ion
BioLargo’s Celinity battery technology was created to provide a better option for battery energy storage than lthiunion, empowering grid stability and storage of renewable energy. Compared tolithium-ion,Celinity is: ¥ 2 4 2 fA sustamasee EFFICIENT CELLINITY - IZ More sustainable bec 7 Ismore energy
Slide 14: Compared to other Battery Chemistries
Compared to other Battery Chemistries Molten ay BioLargo Sodium-ion calcium Lead acid Perit Battery antimony (Liquid Sodium) Energy density (Wh/kg) 150-190 75-165 low 30-50 45-80 552 Life cycle (down to 80% 3 No lossiin i 'No loss in discharge) 50071000 anil discharge baie = discharge ‘Open circuit
Slide 15: Products
Products
Slide 16: We need better batteries
We need better batteries Data Center & Al Infrastructure Boom, Resilience Balancing Arbitrage — buy low & sell high Enabling Renewable Energy- Intermittency
Slide 17: Independent Evaluation Confirms Breakthrough Performance
Sa ae BioLargo k EN=RGY TECHNOLOGIES Independent Evaluation Confirms Breakthrough Performance of BioLargo’s Cellinity Battery Technology for Grid-Scale Energy Storage *See Press Release 6/18/25
Slide 18: Commercialization Pathway and Valuation Roadmap
BioLargo Commercialization Pathway and ENERGY Valuation Roadmap TECHNOLOGIES $43 million valuation — . third-party $1.5 billion NPV >$2.5 billion ‘Complete pilot lidatic Build Cellinit noses seams | vakdaton ey ‘ctore Sy cared me aia Bull component ‘manufacturing support fcity Make and tet Secure ma
Slide 19: Globally Scalable: sell factories, not batteries
Globally Scalable Business model: sell factories, not batteries Factories that are owned and operated locally, with BioLargo holding a minority position Adapt capacity to meet demand scale: giga- vs micro-factory Why own a Cellinity factory? * Best available battery for a hungry market * Capitalize
Slide 20: Revenue Streams
Revenue Streams hy saci ‘+ 6% royalty on gross sales « Target 19% BETI ownership © Each factory will cost ‘+ ~$30 million per factory of each factory $100 million capital cost once at capacity + ~$10-15 million per factory © ~$50 million will run Share in monetization of through BETI's books taxcred
Slide 21: Giga Factory Model - Summary
Giga Factory Model - Summary (Cap-X = $170 million at Scale Annual NOI $80-$90 Million) cman Se, So). Stal Sl Co = ee Ps ee eae eee Eraencancan | sen | Seema] menue] eee sxue Essen snc mice) ieee) eee] aes] ean {GROSS REVENUE] #_sn6onars|§ 175743750] 042500] f7a228605]$ "76218470 —— mate |: teae|s m
Slide 22: BETI Roll-Up Model: Factory Development & Operation
BETI Roll-Up Model: Factory Development & Operation 11 BioLargo Cellinity™ Royalty income % per year EN - R GY = = BETI Equity Capital Distribution 19% per year TECHNOLOGIES Se vert tee | ves vee Yes Need oeeenn on rae 0 36 co % %s 3 % 35 (Sn Sarton wf? | H iioo ' Ramme|’ ewan ° ‘Stance * ‘ctasam| t
Slide 23: MOUs for Factory Projects with partners
MOUs for Factory Projects with partners + innovative financing strategies to create big wins for the communities and BioLargo* + Arizona * Texas + Latin America + New Jersey + Norway + Africa + Puerto Rico + Tribal Lands
Slide 24: The BioLargo Portfolio Addresses AI Infrastructure Chokepoints
The BioLargo Portfolio Addresses Al Infrastructure Chokepoints (@Biokerao BioLargo * Cellinity batteries We Make Life Better * Supply chain independence * Water reuse - Up to 90% water reduction BioLargo Al Solutions + PFAS & contaminant management * Recycling (sBietarge | ae
Slide 25: PFAS and Other Water Treatment Technologies
PFAS and Other Water Treatment Technologies + (New Jersey) — AEC unit delivered, waiting : on completion of supporting infrastructure BioLargo + US and State EPA — cooperation / validation ToUrpnenT« SOUTIONS TeOMOLOGIES + Industry pilots in development * Garratt Callahan * Strategic partnerships in
Slide 26: PFAS Performance Breakthroughs
PFAS and Other Water Treatment Technologies >. BioLargo Performance Breakthroughs Performance Breakthroughs: = Removes PFAS to less than 4 ppt (exceeds new EPA advisory) = Removed ultrashort PFAS including TFA — rare industry capability* = 90% reduction in AEC energy needs** *See Press Release 9/29/
Slide 27: Pooph Update
‘We Make Life Better ri BioLargo Pooph Update BioLargo Protects Its Intellectual Property That Built a National Brand - Pooph's License Was Revoked for Non-Payment and Unauthorized Activities “our technology the foundation tat bul the Pooph bran and made it ‘succesful sai Dons P. Calvert, Presider a
Slide 28: ONM Environmental
ONM Environmental * Our technology built a national brand, working to reposition with a new partner for pet products w + Industrial odor control business continues (Bitewe | aa
Slide 29: Engineering & Environmental Services
Engineering & Environmental Services \©}BioLargo ‘Trgreeny Somes aes Expanding Our Reach Strategic Value Strengthens core technology commercialization Innovation specialists (Biota | 20
Slide 30: Revenue by Year and Q3 Financial Metrics
Millions Revenue by Year The Pooph Effect! SSS EES SS 00 2028 200 2025 (st) “Trends are not necessarily indicative of future performance, and future revenues are highly dependent on our partners’ performance. Q3 Financial Metrics Revenue + $1.21 million vs $4.35 milion in Q3 2024 SGBA + $365 milion
Slide 31: The Major Components of Net Loss
The Major Components of Net Loss 3 Net Loss (%) YTD Net Loss (%6) Pooph Clyra— + Note: Intercompany Balance and Deferred Revenue for BLEST requires discussion (Bitar |
Slide 32: The BioLargo Family of Companies
The BioLargo Family of Companies BioLargo nc. isa sustainable science, technology & full-service enviromental engineering company that makes life better by delivering world-class products and services across abroad range of industries, witha drive to deliver ‘lean water clean air, and advanced antim